C4 Therapeutics Inc
NASDAQ:CCCC
C4 Therapeutics Inc
NASDAQ:CCCC
Price:
6.74 USD
4.82%
Market Closed
Updated:
May 5, 2024
C4 Therapeutics Inc
Income from Continuing Operations
|
C4 Therapeutics Inc
Income from Continuing Operations Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
Income from Continuing Operations
-$132.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-53%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Income from Continuing Operations
$4.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Income from Continuing Operations
$456m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-21%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Income from Continuing Operations
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Income from Continuing Operations
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
11%
|
CAGR 10-Years
25%
|
See Also
What is C4 Therapeutics Inc's Income from Continuing Operations?
Income from Continuing Operations
-132.5m
USD
-132.5m
USD
Based on the financial report for Dec 31, 2023, C4 Therapeutics Inc's Income from Continuing Operations amounts to -132.5m USD.
What is C4 Therapeutics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-53%
-53%
Over the last year, the Income from Continuing Operations growth was -3%. The average annual Income from Continuing Operations growth rates for C4 Therapeutics Inc have been -26% over the past three years , -53% over the past five years .
You don't have any saved screeners yet
